Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of voluntary functions, including breathing, swallowing, use of limbs, and, eventually, death. Two treatments are approved for ALS in the markets under study—Mitsubishi Tanabe Pharma’s Radicava (edaravone) and riluzole (Sanofi’s Rilutek, other brands, generics)—but pressing unmet need remains. Although the ALS pipeline comprises diverse programs designed to be neuroprotective, enhance respiratory function, or restore lost neurons in the spinal cord, clinical success in ALS has historically been a formidable challenge. Thus, substantial clinical and commercial opportunity awaits developers that can develop a safe, effective therapy for this crippling disease.
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Niche & Rare Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.